JAAOS - 2026-11-01 - Journal Article; Comparative Study
Declining Medicare Reimbursement for Total Ankle Arthroplasty: A Comparison of Podiatrists and Orthopaedic Surgeons, 2014 to 2023.
Ferdon RJ, Minerva AJ, Moore JW, Jacques B, George KD, Ravinsky RA, Gross CE, Silvestre J
Topics
Key Takeaway
Inflation-adjusted Medicare reimbursement for total ankle arthroplasty declined 18–24% from 2014 to 2023, with podiatrists experiencing a 36% drop in annual procedural income versus 22% for orthopaedic surgeons.
Summary Depth
Choose how much analysis to show on this article page.
Summary
This study analyzed CMS Medicare Physician and Other Practitioners database data for CPT 27702 from 2014 to 2023 to compare reimbursement trends between orthopaedic surgeons and podiatrists performing TAA. Podiatrists received $61 more per procedure ($890 vs. $829, p=0.033) and had a higher mean payment ratio (0.25 vs. 0.21, p=0.004), but annual procedural income did not differ significantly between specialties (p=0.409). After CPI adjustment, real reimbursement fell 24% for podiatrists and 18% for orthopaedic surgeons, with API declining 36% and 22%, respectively.
Key Limitation
The study captures only Medicare fee-for-service billing and cannot account for private payer, bundled payment, or facility fee revenue streams that may offset or amplify the observed reimbursement declines.
Original Abstract
BACKGROUND
Total ankle arthroplasty (TAA) is a well-established motion-preserving treatment for end-stage ankle arthritis. Although utilization has increased, declining Medicare payments for orthopaedic procedures remains a growing concern. Limited data exist comparing Medicare reimbursement trends for TAA between orthopaedic surgeons and podiatrists performing this procedure.
METHODS
A retrospective analysis of the Centers for Medicare & Medicaid Services Medicare Physician and Other Practitioners database was done from 2014 to 2023 using Current Procedural Terminology code 27702. Providers billing ≥10 TAA procedures annually were included and stratified by specialty. Provider demographics, geographic distribution, mean reimbursement (average Medicare standardized amount), and annual procedural income (API) were analyzed. All payments were adjusted to 2023 US dollars using the Consumer Price Index. Statistical comparisons were made with t -tests and Chi-squared analyses with alpha set at 0.05.
RESULTS
A total of 388 providers (351 orthopaedic surgeons, 37 podiatrists) performed 6,263 TAAs for Medicare beneficiaries over the study period. Podiatrists represented 9.5% of all providers and 8.3% of all TAA procedures. Podiatrists were reimbursed $61 (7.4%) more per TAA than orthopaedic surgeons ($890 ± $138 vs. $829 ± $167; P = 0.033) and had a higher mean payment ratio (0.25 ± 0.07 vs. 0.21 ± 0.11; P = 0.004). No notable differences existed in mean APIs between podiatrists and orthopaedic surgeons ( P = 0.409). After inflation adjustment, reimbursement decreased 24% for podiatrists and 18% for orthopaedic surgeons, corresponding to API declines of 36% and 22%, respectively, over the study period.
CONCLUSIONS
Between 2014 and 2023, Medicare reimbursement for TAA declined markedly for foot and ankle surgeons. Continued reductions in Medicare payments may threaten practice sustainability and patient access to specialized foot and ankle reconstructive care.